循環器ジャーナル71巻4号

2023年10月発行

特集 変革期を迎えた肺高血圧症—次世代の病態理解，診断，治療とは？ Ⅱ.各論：各種肺高血圧症の診断と治療

PAH治療薬②：PDE5阻害薬とsGC刺激薬

著者： 平川今日子¹ 山本英一郎¹ 辻田賢一¹

所属機関： ¹熊本大学病院循環器内科

ページ範囲：P.510 - P.514

POINT
●肺血管拡張薬には3経路存在し，そのうちの一つに一酸化窒素（NO）経路に作用する薬剤がある．
●NO経路の肺血管拡張薬としてはPDE5阻害薬，sGC刺激薬が存在する．

参考文献

1）Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003 ; 167 : 1139-41.

2）Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003 ; 108 : 2066-9.

3）Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005 ; 353 : 2148-57.

4）Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009 ; 119 : 2894-903.

5）Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the treatment of pulmonary arterial hypertension : a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 2012 ; 60 : 768-74.

6）日本循環器学会，日本肺高血圧・肺循環学会，日本呼吸器学会，他．肺高血圧症治療ガイドライン（2017年改訂版）．2018

7）Ogawa A, Satoh T, Tamura Y, et al. Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension. Am J Cardiol 2017 ; 119 : 1479-84.

8）Tamura Y, Kumamaru H, Inami T, et al. Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan. JACC Asia 2022 ; 2 : 273-84.

9）Galie N, Barbera JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 2015 ; 373 : 834-44.

10）Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022 ; 43 : 3618-731.

11）Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013 ; 369 : 330-40.

12）Archer SL, Djaballah K, Humbert M, et al. Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension. Am J Respir Crit Care Med 1998 ; 158 : 1061-7.